NeuroSense Shares Surge Over 400% As FDA Clears Initiating PK Study Of PrimeC

NeuroSense (NASDAQ: NRSN) shares surge over 400% as they receive clearance from the FDA to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.